Industry: Pharmaceuticals, Biotechnology
BioAxone was founded in April 2000 to commercialize Rho GTPase inhibition as a potential target for nerve regeneration in the CNS. Related technologies were licensed in from the University of Montreal. During the initial seed round the Company raised $550,000, which was followed in June 2002 and April 2005 by two additional rounds, raising a total of $23.7M through the combined investment of four Montreal-based VC firms (Desjardins Venture Capital, Fonds de solidarité FTQ, T2C2, and Multiple Capital). ( www.bioaxone.com )
BioAxone Therapeutic Inc.
3575 Avenue Du Parc, Suite 5322
Montreal, Quebec H2X 3P9
Canada
Tel: (514) 282-9990